Current Treatment Options for RET Lung Cancer
Lung cancer staging matters. Why? So your doctor can properly assess the spread of disease…
rdsupportJune 5, 2024
IASLC Targeted Therapies Recap
#TogetherSeparately: live virtual meetup to summarize data presented on February’s IASLC Targeted Therapies Meeting. March 13 at 3PM…
rdsupportMarch 11, 2024
RET inhibitor Granted Fast Track by FDA
Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by FDA Ellipses Pharma…
rdsupportMarch 11, 2024
The Harmonic™ Clinical Trial for Never Smokers
New clinical trial for never smokers: The Harmonic™ clinical trial The Harmonic™ clinical trial is…
rdsupportMarch 9, 2024
Looking Ahead: The Future of Diagnostic Testing for Patients
Over the last fifteen years, the introduction of precision medicine has generated renewed hope for…
rdsupportJanuary 7, 2024
2023 RET Cancer Research Update
2023 Happy Lungs Project RET research update On Friday December 8th, the Happy Lungs Project…
rdsupportDecember 18, 2023
Exciting Preclinical Results About Vepafestinib
New published study with exciting preclinical results about the second generation RET inhibitor vepafestinib (TAS0953/HM06). Vepafestinib showed selectivity…
rdsupportOctober 10, 2023
New clinical trial testing amivantamab
New clinical trial testing amivantamab for patients who progressed on RET therapies: A Phase 1…
rdsupportOctober 8, 2023
Finding the Right Time to Ask About Biomarker Testing
Increasingly, cancer care is being approached with precision medicine methods that can offer personalized medical…
rdsupportJuly 27, 2023
Two research studies funded by HLP presented at 2023 ASCO Mtg
Last week was the 2023 American Society of Clinical Oncology (ASCO) conference in Chicago. The…
rdsupportJune 19, 2023
